Predicted expression of genes involved in the thiopurine metabolic pathway and azathioprine discontinuation due to myelotoxicity. Issue 4 (20th February 2022)

• Record Type: Journal Article
• Authors: Daniel, Laura L.; Dickson, Alyson L.; Zanussi, Jacy T.; Miller‐Fleming, Tyne W.; Straub, Peter S.; Wei, Wei‐Qi; Plummer, W. Dale; Dupont, William D.; Liu, Ge; Anandi, Prathima; Reese, Tyler S.; Birdwell, Kelly A.; Kawai, Vivian K.; Hung, Adriana M.; Cox, Nancy J.; Feng, QiPing; Stein, C. Michael; Chung, Cecilia P.
• Is Part Of: Clinical and translational science. Volume 15:Issue 4(2022)
• Page Start: 859
• Page End: 865
• Publication Date: 2022-02-20
• Subjects: Medicine, Experimental -- Periodicals; Medical innovations -- Periodicals; 616.027
• DOI: 10.1111/cts.13243
• Languages: English
• ISSNs: 1752-8054

Abstract

Abstract: TPMT and NUDT15 variants explain less than 25% of azathioprine‐associated myelotoxicity. There are 25 additional genes in the thiopurine pathway that could also contribute to azathioprine myelotoxicity. We hypothesized that among TPMT and NUDT15 normal metabolizers, a score combining the genetically predicted expression of other proteins in the thiopurine pathway would be associated with a higher risk for azathioprine discontinuation due to myelotoxicity. We conducted a retrospective cohort study of new users of azathioprine who were normal TPMT and NUDT15 metabolizers. In 1201 White patients receiving azathioprine for an inflammatory disease, we used relaxed Least Absolute Shrinkage and Selection Operator (LASSO) regression to select genes that built a score for discontinuing azathioprine due to myelotoxicity. The score incorporated the predicted expression of AOX1 and NME1 . Patients in the highest score tertile had a higher risk of discontinuing azathioprine compared to those in the lowest tertile (hazard ratio [HR] = 2.15, 95% confidence interval [CI] = 1.11–4.19, p = 0.024). Results remained significant after adjusting for a propensity score, including sex, tertile of calendar year at initial dose, initial dose, age at baseline, indication, prior TPMT testing, and the first 10 principal components of the genetic data (HR = 2.11, 95% CI = 1.08–4.13, p = 0.030). We validated the results in a cohort ( N = 517 non‐White patients and those receiving azathioprine to prevent transplant rejection) that included all other patients receiving azathioprine (HR = 2.00, (95% CI = 1.09–3.65, p = 0.024). In conclusion, among patients who were TPMT and NUDT15 normal metabolizers, a score combining the predicted expression of AOX1 and NME1 was associated with an increased risk for discontinuing azathioprine due to myelotoxicity.